Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYTX-011 in advanced NSCLC
NCT05652868Phase 1Terminated
- Sponsor
- Mythic Therapeutics
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of mytx-011 in non-small cell lung cancer (NSCLC) (9 arms), sponsored by Mythic Therapeutics. Primary endpoints: Dose Limiting Toxicity at 21 days and Objective Response Rate at 2 years. Started Mar 2023; status: terminated.
02
Drugs
mytx-011
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05652868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652868.